Cardiomyopathy

Clinical Trial Finder

Many patients with cardiomyopathy are interested in participating in the latest research regarding their condition. This Clinical Trial Finder can help you—or a loved one—easily find ongoing cardiovascular clinical research trials for which you might qualify. This list is a service of the U.S. National Institutes of Health called clinicaltrials.gov, a database of publicly and privately supported clinical studies.

Simply click on the trial below that interests you to learn how you might participate.

Stress Echo 2020 - The International Stress Echo Study

Conditions:   Coronary Artery Disease;   Heart Failure;   Hypertrophic Cardiomyopathy;   Aortic Valve Disease;   Athletes Heart;   Tetralogy of Fallot;   Pulmonary Arterial Hypertension
Interventions:   Procedure: Left ventricular contractile reserve SE;   Procedure: B-lines SE;   Procedure: Left ventricular outflow tract gradient SE;   Procedure: Diastolic function SE;   Procedure: Mitral regurgitation SE;   Procedure: Pulmonary hemodynamics SE;   Procedure: Coronary flow reserve SE
Sponsors:   Fatebenefratelli Hospital;   Institute of Clinical Physiology, CNR, Pisa,Italy;   Salerno Hospital, Italy;   Monaldi Hospital, Napoli, Italy;   University of Pisa, Italy;   San Luca Hospital, Lucca, Italy;   Careggi University Hospital, Florence, Italy;   Federico II University, Napoli, Italy;   San Carlo Hospital, Potenza, Italy;   Royal Brompton & Harefield NHS Foundation Trust;   Ospedale dell'Angelo, Venezia-Mestre, Italy;   University of Parma;   Hospital Clinics, Trieste, Italy;   Rio Grande do Sul University Hospital, Porto Alegre, Brasil;   Hospital San José, Criciuma, Brasil;   Hospital San Vicente de Paulo, Passo Fundo, Brasil;   University of Belgrade;   University of Szeged, Hungary;   Elisabeth Hospital, Hodmezovasarhely, Hungary;   University of Padua, Italy;   Sandro Pertini Hospital, Rome, Italy;   Medical Center Hospital of the Republic of Kazakhstan, Astana, Kazakhstan;   Hospital Clinics, Bari, Italy;   Ospedale Nottola, Siena, Italy;   University of Catania, Italy;   Medika Cardiocenter, Saint Petersburg, Russian Federation
Recruiting - verified February 2017

EMPagliflozin outcomE tRial in Patients With chrOnic heaRt Failure With Preserved Ejection Fraction (EMPEROR-Preserved)

Condition:   Heart Failure
Interventions:   Drug: Empagliflozin;   Drug: Placebo
Sponsors:   Boehringer Ingelheim;   Eli Lilly and Company
Not yet recruiting - verified February 2017

EMPagliflozin outcomE tRial in Patients With chrOnic heaRt Failure With Reduced Ejection Fraction (EMPEROR-Reduced)

Condition:   Heart Failure
Interventions:   Drug: Empagliflozin;   Drug: Placebo
Sponsors:   Boehringer Ingelheim;   Eli Lilly and Company
Not yet recruiting - verified February 2017

Efficacy of Dotarem® (Gd-DOTA) Versus Magnevist® (Gd-DTPA) for Late Gadolinium Enhancement Cardiac Magnetic Resonance

Conditions:   Coronary Artery Disease;   Cardiomyopathy
Interventions:   Drug: Dotarem® (Gd-DOTA);   Drug: Magnevist® (Gd-DTPA)
Sponsors:   Dipan Shah;   Guerbet
Enrolling by invitation - verified February 2017

UTSW HP [13-C] Pyruvate Injection in HCM

Condition:   Cardiomyopathy, Hypertrophic
Intervention:   Drug: Hyperpolarized 13C-Pyruvate
Sponsor:   University of Texas Southwestern Medical Center
Not yet recruiting - verified February 2017

Assessment of Myocardial Ischemic-Reperfusion Injury During Off- and On- Pump CABG

Conditions:   Ischemic Heart Disease;   Coronary Artery Disease;   Ischemic Reperfusion Injury;   CABG
Interventions:   Procedure: On-Pump CABG.;   Procedure: Off-Pump CABG.;   Procedure: BH-CABG MSC.
Sponsor:   St. Petersburg State Pavlov Medical University
Recruiting - verified February 2017

Safety and Efficacy of the Symetis ACURATE Neo/TF Compared to the Edwards SAPIEN 3 Bioprosthesis.

Condition:   Aortic Valve Stenosis
Interventions:   Device: Symetis ACURATE neo/TF transfemoral TAVI system;   Device: Edwards Sapien 3 Transcatheter Heart Valve
Sponsors:   University Hospital Inselspital, Berne;   Kerckhoff Heart Center
Recruiting - verified February 2017

Open-Label Study of Perhexiline in Patients With Hypertrophic Cardiomyopathy and Moderate to Severe Heart Failure

Conditions:   Cardiomyopathy, Hypertrophic;   Cardiomyopathy, Hypertrophic, Familial
Intervention:   Drug: Perhexiline
Sponsor:   Heart Metabolics Limited
Recruiting - verified February 2017

Long-term Safety of Tafamidis in Subjects With Transthyretin Cardiomyopathy

Condition:   Transthyretin (TTR) Amyloid Cardiomyopathy
Intervention:   Drug: Tafamidis meglumine
Sponsor:   Pfizer
Recruiting - verified February 2017

Combined Spinal- Epidural Anesthesia in Patients With Dilated Cardiomyopathy

Condition:   Cardiomyopathies
Intervention:   Other: combined spinal epidural anesthesia
Sponsor:   Assiut University
Completed - verified February 2017

Advancing Symptom Alleviation With Palliative Treatment

Conditions:   Heart Failure;   Pulmonary Disease, Chronic Obstructive;   Emphysema
Intervention:   Behavioral: ADAPT Intervention
Sponsor:   VA Office of Research and Development
Recruiting - verified February 2017

Hypertrophic Cardiomyopathy Symptom Release by BX1514M

Condition:   Hypertrophic Cardiomyopathy
Interventions:   Drug: Treatment BX1514M;   Drug: Placebo;   Other: Walk distance test;   Other: Exercise echocardiography
Sponsor:   University Hospital, Bordeaux
Completed - verified February 2017

Doxorubicin With Upfront Dexrazoxane Plus Olaratumab for the Treatment of Advanced or Metastatic Soft Tissue Sarcoma

Conditions:   Sarcoma, Soft Tissue;   Soft Tissue Sarcoma;   Undifferentiated Pleomorphic Sarcoma;   Leiomyosarcoma;   Liposarcoma;   Synovial Sarcoma;   Myxofibrosarcoma;   Angiosarcoma;   Fibrosarcoma;   Malignant Peripheral Nerve Sheath Tumor;   Epithelioid Sarcoma
Interventions:   Drug: Dexrazoxane;   Drug: Doxorubicin;   Drug: Olaratumab
Sponsor:   Washington University School of Medicine
Recruiting - verified February 2017

Safety & Efficacy of Intramyocardial Injection of Mesenchymal Precursor Cells on Myocardial Function in LVAD Recipients

Conditions:   Heart Failure;   Cardiomyopathy;   Ventricular Dysfunction
Interventions:   Biological: MPC Intramyocardial Injection;   Drug: Control Solution
Sponsors:   Annetine Gelijns;   National Heart, Lung, and Blood Institute (NHLBI)
Recruiting - verified February 2017

A Rollover Study of ARRY-371797 in Patients With LMNA-Related Dilated Cardiomyopathy

Condition:   LMNA-Related Dilated Cardiomyopathy
Intervention:   Drug: ARRY-371797, p38 inhibitor, oral
Sponsor:   Array BioPharma
Recruiting - verified February 2017

Efficacy and Safety of Implantable Cardioverter-Defibrillator (ICD) Implantation in the Elderly

Conditions:   Cardiomyopathy;   Coronary Artery Disease;   Congestive Heart Failure;   Myocardial Infarction
Interventions:   Device: Implantable Cardioverter Defibrillator;   Other: Optimal Medical Therapy
Sponsor:   VA Office of Research and Development
Recruiting - verified February 2017

Genotype-Phenotype Associations in Pediatric Cardiomyopathy (PCM GENES)

Conditions:   Dilated Cardiomyopathy;   Hypertrophic Cardiomyopathy;   Restrictive Cardiomyopathy
Intervention:  
Sponsors:   Wayne State University;   New England Research Institutes;   Children's Hospital Medical Center, Cincinnati;   Washington University School of Medicine;   Children's Hospital of Philadelphia;   Columbia University;   Boston Children’s Hospital;   Ann & Robert H Lurie Children's Hospital of Chicago;   Primary Children's Hospital;   Monroe Carell Jr. Children's Hospital at Vanderbilt;   Stollery Children's Hospital;   National Heart, Lung, and Blood Institute (NHLBI);   University of Miami;   Children's Hospital Colorado;   Indiana University
Active, not recruiting - verified February 2017

Cardiac Biomarkers in Pediatric Cardiomyopathy (PCM Biomarkers)

Conditions:   Dilated Cardiomyopathy;   Hypertrophic Cardiomyopathy
Intervention:  
Sponsors:   Wayne State University;   New England Research Institutes;   Washington University School of Medicine;   Boston Children’s Hospital;   Columbia University;   Children's Hospital of Philadelphia;   Ann & Robert H Lurie Children's Hospital of Chicago;   Primary Children's Hospital;   Monroe Carell Jr. Children's Hospital at Vanderbilt;   Stollery Children's Hospital;   Children's Hospital Medical Center, Cincinnati;   Montefiore Medical Center;   Children's Hospital Colorado;   Le Bonheur Children's Hospital;   Children's Hospital of Pittsburgh
Active, not recruiting - verified February 2017

Functional Impact of GLP-1 for Heart Failure Treatment (FIGHT)

Condition:   Acute Heart Failure
Interventions:   Drug: Liraglutide;   Drug: Placebo
Sponsors:   Duke University;   National Heart, Lung, and Blood Institute (NHLBI)
Completed - verified February 2017